Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream plus autologous blood therapy for non-segmental vitiligo
ChiCTR2600135077Phase 4Not yet recruiting
- Sponsor
- Guangzhou Institute of Dermatology
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib in Vitiligo, sponsored by Guangzhou Institute of Dermatology. Primary endpoint: Proportion of patients with at least 75% improvement in F-VASI. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2600135077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135077.